TERMIUM Plus^®

Record 1,  Textual support,  English

Record number: 1, Textual support number: 1 OBS

Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act(also known as The Jean Chrétien Pledge to Africa), received Royal Assent on May 14, 2004. Bill C-9 implements a decision made on August 30, 2003, by member countries of the World Trade Organization(WTO) to waive certain trade obligations that had prevented developed countries from authorizing the export of lower-priced versions of patented medicines to least-developed and developing countries unable to manufacture their own.  2, record 1, English, - An%20Act%20to%20amend%20the%20Patent%20Act%20and%20the%20Food%20and%20Drugs%20Act

Record 1,  Textual support,  French

Record number: 1, Textual support number: 1 OBS

Le projet de loi C-9 sur l'amendement à la Loi sur les brevets et à la Loi sur les aliments et drogues du Canada (Loi de l'engagement de Jean Chrétien envers l'Afrique) a reçu la sanction royale le 14 mai 2004. Le projet de loi C-9 met en œuvre la décision prise le 30 août 2003 par les pays membres de l'Organisation mondiale du commerce (OMC) afin de renoncer à certaines obligations commerciales qui empêchaient les pays développés d'autoriser l'exportation de versions à moindre coût de médicaments brevetés dans les pays moins développés ou en développement ayant une capacité insuffisante ou inexistante de production pharmaceutique.  2, record 1, French, - Loi%20modifiant%20la%20Loi%20sur%20les%20brevets%20et%20la%20Loi%20sur%20les%20aliments%20et%20drogues

Record 1,  Textual support,  Spanish

Record 2,  Textual support,  English

Record number: 2, Textual support number: 1 CONT

Every drug receives three distinct names : the chemical name, the generic(or nonproprietary) name, and the brand(or proprietary or trademark) name.... The generic name is commonly used by health care professionals and is usually created when a new drug is ready to be marketed. Although the manufacturer or sponsor of the drug has exclusive right of manufacture during the 17 years of the drug's patent, it never owns the generic name.... In the United States, the generic name must first be approved by the U. S. Adopted Name(USAN) Council and then by the World Health Organization(WHO).... After approving the generic name, the Council submits the name to WHO, which has final approval.... After being approved by WHO, the drug is assigned an international nonproprietary name.  6, record 2, English, - nonproprietary%20name

Record number: 2, Textual support number: 2 CONT

Once a chemical substance has become frequently cited in the literature, it will be identified with simplified nomenclature popularly known as a "generic" name. This nonproprietary name is preferred in database indexing over all other types of drug nomenclature. MEDLINE [registered trademark] cites the United States Adopted Name (USAN) as a standard, when available. USANs are officially approved designations adopted by the FDA for uniformity in labeling and regulatory references. EMBASE®, on the other hand, prefers International Nonproprietary Names (INNs), promulgated by the World Health Organization, as drug descriptors. Caution: the USAN and INN "generic" name for the same drug may differ. Other official nomenclature standards include: British Approved Name (BAN), Nordiska Farmakopenamden (NFN), and Dénomination Commune Francaise (DCF).  7, record 2, English, - nonproprietary%20name

Record 2,  Textual support,  French

Record number: 2, Textual support number: 1 DEF

Nom auquel ne s'attache aucun droit de propriété, tels les noms officiellement agréés, les noms de pharmacopée ou les dénominations libres.  3, record 2, French, - d%C3%A9nomination%20commune

Record 2,  Textual support,  Spanish

Record 3,  Textual support,  English

Record number: 3, Textual support number: 1 CONT

A non-patented medicine is a drug that is not protected by a patent, including generic drugs and some brand name drugs.  4, record 3, English, - unlicensed

Record number: 3, Textual support number: 2 CONT

Where any person passes any unpatented product off as patented product or passes any unpatented process off as patented process, such person shall be ordered by the administrative authority for patent affairs to stop the passing off, correct it publicly, and pay a fine.  5, record 3, English, - unlicensed

Record 3,  Textual support,  French

Record number: 3, Textual support number: 1 CONT

Un médicament non breveté est un médicament qui ne bénéficie pas de la protection d'un brevet. Les médicaments génériques et certains médicaments de marque s'inscrivent dans cette catégorie de médicaments.  2, record 3, French, - non%20brevet%C3%A9

Record 3,  Textual support,  Spanish

Record 4,  Textual support,  English

Record number: 4, Textual support number: 1 CONT

Every drug receives three distinct names : the chemical name, the generic(or nonproprietary) name, and the brand(or proprietary or trademark) name.... The generic name is commonly used by health care professionals and is usually created when a new drug is ready to be marketed. Although the manufacturer or sponsor of the drug has exclusive right of manufacture during the 17 years of the drug's patent, it never owns the generic name.... In the United States, the generic name must first be approved by the U. S. Adopted Name(USAN) Council and then by the World Health Organization(WHO).... After approving the generic name, the Council submits the name to WHO, which has final approval.... After being approved by WHO, the drug is assigned an international nonproprietary name.  5, record 4, English, - international%20nonproprietary%20name

Record 4,  Textual support,  French

Record number: 4, Textual support number: 1 DEF

dénomination commune internationale : Nom proposé par l'OMS [Organisation mondiale de la santé] pour désigner la substance qui sert de principe actif dans une préparation pharmaceutique.  3, record 4, French, - d%C3%A9nomination%20commune%20internationale

Record 4,  Textual support,  Spanish

Record 5,  Textual support,  English

Record number: 5, Textual support number: 1 CONT

The amendment basically guarantees the producer of brand name drugs(the developers of new pharmaceuticals) up to ten years of exclusive rights to then newly patent products.  1, record 5, English, - developer

Record 5,  Textual support,  French

Record 5,  Textual support,  Spanish